Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
In this study the investigators investigate a cell therapy strategy that could harness
allogeneic effectors that can potentially mediate anti-lymphoma effect. The investigators
have designed a novel lymphodepleting conditioning regimen followed by infusion of
donor-derived natural killer (NK) cells and interleukin-2 (IL-2) for patients with refractory
lymphoid malignancies.